CHICAGO -- Adding an EGFR inhibitor to chemotherapy significantly improved overall survival (OS) in advanced KRAS wild-type pancreatic cancer, a randomized trial showed. Median OS improved from 8.5 ...

Practice guidelines recommend panitumumab with chemotherapy to treat KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients. However, not all patients respond to this therapy. We propose a ...

Gut microbiota signatures associated with KRAS mutations in patients with colorectal cancer (CRC) have been identified by researchers. Their findings suggest that the gut microbes may serve as ...

Role of trimodality therapy versus dual-modality in T3N0 rectal cancer patients. Background: Prior clinical data suggest a dose-related response to cmab when combined with irinotecan in pts with KRAS ...

Avutometinib and defactinib combination shows over one-year median PFS in recurrent LGSOC patients, with notable efficacy in KRAS-mutant and KRAS-wild-type populations. Verastem Oncology plans FDA ...

Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors BI-2493 and BI-2865, both being developed for the treatment of cancer.

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Potentially targetable oncogenic rearrangements are more prevalent among patients with KRAS wild-type ...

ELOVL6 is an acyltransferase involved in the synthesis of saturated and monounsaturated fatty acids. New work finds that inhibition of ELOVL6 function results in mislocalization of oncogenic KRAS from ...

Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.

Please provide your email address to receive an email when new articles are posted on . Perioperative complication rates were similar between simultaneous and delayed resection of liver metastasis and ...